It is made available under a CC-BY-NC 4.0 International license .

1

1	Impact of Fludrocortisone on the Outcomes of Subarachnoid Hemorrhage Patients: A
2	Retrospective Analysis
3	Akshitkumar M. Mistry, MD ¹ ; Janki Naidugari, BS; ² Michael J. Feldman, MD ³ ; Jordan A.
4	Magarik, MD, MS ³ ; Dale Ding, MD ¹ ; Isaac J. Abecassis, MD; ¹ Matthew W. Semler, MD, MSc; ⁴
5	Todd W. Rice, MD, MSc ⁴
6	
7	¹ Department of Neurosurgery, University of Louisville, Louisville, KY, USA; ² School of Medicine,
8	University of Louisville, Louisville, KY, USA; ³ Department of Neurosurgery, Vanderbilt University
9	Medical Center, Nashville, TN, USA; ⁴ Department of Medicine, Division of Allergy, Pulmonary,
10	and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
11	
12	Corresponding Author:
13	Akshitkumar M. Mistry, MD
14	Department of Neurological Surgery, 220 Abraham Flexner Way, 15th Floor,
15	University of Louisville, Louisville, KY 40202
16	Telephone: 502-407-3226; Fax: 502-582-7477; E-mail: axitamm@gmail.com
17	
18	Funding: was provided by the Vanderbilt Institute for Clinical and Translational Research
19	(UL1TR000445 and UL1TR002243 from NCATS/NIH).
20	Short title: Fludrocortisone improves SAH outcomes
21	Keywords: Subarachnoid hemorrhage; Fludrocortisone; Critical Care; Mineralocorticoid
22	
23	Disclosures: Isaac Abecassis has the following disclosures: 1) Remedy Robotics: Consultant,
24	Equity. 2) IschemaView Inc/Rapid AI: Clinical consultant. 3) Rapid Medical: Consultant. 4) Balt:

25 Consultant. 5) CNS Foundation: Grant Research Support.

2

26 ABSTRACT

Background: Whether the use of fludrocortisone affects outcomes of patients with aneurysmal
 subarachnoid hemorrhage (aSAH) and its usage rate in the United States remain unknown.

Methods: We conducted a retrospective analysis of 78 consecutive patients with a ruptured 29 aSAH at a single academic center in the United States. The primary outcome was the score on 30 the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. We adjusted 31 the primary outcome for age, hypertension, aSAH grade, and time from aSAH onset to 32 aneurysm treatment. Secondary outcomes were brain and cardiopulmonary dysfunction events. 33 **Results:** Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 34 64% were female, and 41 (53%) received fludrocortisone. The adjusted common odds ratio, 35 aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95% 36 37 CI, 0.14-0.80; P=0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different: delayed cerebral ischemia (22% vs. 39%, P=0.16); 38 cardiac dysfunction (0% vs. 11%; P=0.10); and pulmonary edema (15% vs. 8%; P=0.59). 39 **Conclusions**: The risk of disability or death at 90 days was lower with the use of fludrocortisone 40

40 **Conclusions**. The fisk of disability of death at 90 days was lower with the use of hudrocon41 in aSAH patients.

3

43 INTRODUCTION

Inpatient and overall mortality of patients with aneurysmal subarachnoid hemorrhage (aSAH) are 20% (1-3) and 40%, respectively (4). The high morbidity and mortality result from life-threatening neurological sequelae like re-hemorrhage, cerebral swelling, and vasospasm, which leads to ischemic strokes, as well as non-neurological complications like fatal volume loss from cerebral salt wasting (kidney-drive natriuresis), acute kidney injury (AKI), and cardiopulmonary injury (5-7).

Patients with aSAH can have fatal polyuria (>4 liters/day) from natriuresis (8, 9). Thus, they require incredibly large volumes of intravenous fluids to maintain their intravascular volume (8-10). Hence, fluid therapy is the most common therapy aSAH patients receive. In the presence of natriuresis-driven polyuria, fluid administration is among the most considerable challenges in the medical management of aSAH patients. Failure to do so can compromise multi-organ perfusion, increasing the risk of life-threatening ischemic strokes, cardiopulmonary dysfunction, and AKI (11).

57 Fludrocortisone is well-known to reduce natriuresis and hyponatremia, but its effects on outcomes in aSAH patients have not been studied. Using data from a prospective study and two 58 59 phase 2 randomized controlled trials, we have shown that fludrocortisone decreases natriuresis, hyponatremia, and polyuria in aSAH patients, leading to lower fluid and sodium requirements 60 61 and hypovolemic incidences (8). Importantly, a meta-analysis of the studies shows that it lowers the rate of symptomatic vasospasm (8). The 2023 American Heart Association aSAH guidelines 62 recommend that "the use of mineralocorticoids is reasonable to treat natriuresis and 63 hyponatremia" (12). 64

However, the impact of fludrocortisone on the clinical outcomes of aSAH patients has yet to be studied. Therefore, to fill this knowledge gap, we conducted a retrospective analysis of aSAH patients enrolled in the SMART randomized trial,(13) comparing outcomes of patients

It is made available under a CC-BY-NC 4.0 International license .

4

treated with fludrocortisone with those not treated with fludrocortisone. We hypothesized that,

69 because of the established efficacy of fludrocortisone, its use would result in less death or

disability, as measured by the modified Rankin Scale (14) (mRS), at 90 days.

71

72 METHODS

73 Study Design and Patient Selection

We conducted a retrospective cohort analysis of all aSAH patients enrolled in the Isotonic <u>Solutions and Major Adverse Renal Events Trial (SMART)(13)</u> after its results and data of aSAH patients were available. SMART was a pragmatic, unblinded, cluster-randomized, multiple-crossover clinical trial (ClinicalTrials.gov: NCT02444988, NCT02547779) conducted at an academic medical center in the United States between June 1, 2015, and April 30, 2017. Trial protocol did not control the use of fludrocortisone. This subanalysis was approved by the institutional review board at Vanderbilt University Medical Center (IRB # 141349).

81

82 Data Collection

Data for aSAH patients were collected retrospectively blinded to fludrocortisone use. The 83 84 following co-variables were collected: past medical history (hypertension, diabetes, ischemic heart disease, tobacco use, and prior aSAH): aSAH severity as measured on Hunt and Hess 85 86 scale, the World Federation of Neurological Surgeons (WFNS) grading system, and the modified Fischer scale; location, largest linear measurement, and treatment procedure 87 (endovascular embolization vs. clip obliteration) of the ruptured aneurysm; time from symptom 88 onset to procedural intervention; new stroke (iatrogenic or spontaneous aneurysmal re-rupture); 89 90 development of hydrocephalus requiring ventricular cerebrospinal fluid drainage; and infection of the central nervous system, meninges, or cerebrospinal fluid (microbiologically proven or 91 clinical signs treated empirically with 4 or more consecutive days of antibiotics). 92

It is made available under a CC-BY-NC 4.0 International license .

5

93

94 Study Intervention: Fludrocortisone Administration

The general institutional practice was to maintain euvolemia in aSAH patients and treat electrolyte imbalances. There was no institutional protocol to maintain euvolemia and treat hyponatremia. The use of fludrocortisone (dosage regimen and length), enteral salt, and/or hypertonic saline was provider dependent. Fludrocortisone was frequently initiated in patients with vasospasm who were at risk of hypovolemia. In this cohort, fludrocortisone was started as early as the 3rd day of ICU admission and maintained for the majority of ICU stay.

101

102 Study Outcomes

Our study outcomes were not part of the SMART trial. Our primary outcome was the ordinal score on the mRS (14) (range, 0 [no symptoms] to 6 [death]) around 90 days. It was collected prospectively as part of routine clinical follow-up. Secondary outcomes included:

the 21-day incidence of symptomatic vasospasm (defined as at least a 2-point 106 decrease in Glasgow coma score or 2-point increase in the motor score of the 107 National Institutes of Health Stroke Scale lasting for at least 8 hours after 108 exclusion of attributable cerebral and non-cerebral conditions) and delayed 109 cerebral ischemia (defined as a presence of a new, post-operative hyperintensity 110 on diffusion-weighted magnetic resonance imaging, or a new, permanent focal 111 neurological deficit, or a permanent decrease on Glasgow coma score of at least 112 2 points unattributable to other cerebral and non-cerebral conditions); (15, 16) 113

- total amount of fludrocortisone, enteral sodium chloride, and hypertonic saline
 (3% sodium chloride) received during the hospitalization;
- cardiac dysfunction defined as myocardial infarction, new onset of heart failure,
 or initiation of inotropic therapy;

It is made available under a CC-BY-NC 4.0 International license .

6

118

119

 pulmonary edema evidenced by a chest radiograph or diuretic treatment with the goal of treating pulmonary edema.

120

121 Statistical Analysis

122 Chi-square test for categorical data and the Wilcoxon test for continuous data were utilized for between-group comparisons without adjustment for covariates. The primary analysis 123 compared 90-day mRS scores treated as an ordinal variable between patients treated with and 124 without fludrocortisone using a proportional odds regression model, adjusting for age, history of 125 hypertension, time from aSAH onset to aneurysm treatment, procedure received (clip or 126 embolization), and the WFNS grade at baseline. This outcome was not assessed at the 90-day 127 timepoint in 6 patients; thus for them, the last known mRS score was carried forward. To assess 128 129 the robustness of the primary analysis, we performed three sensitivity analyses in which we repeated the primary analysis: 1) excluding patients with missing 90-day mRS scores: 2) 130 substituting the mRS scores with values imputed using multivariate imputation by chained 131 equations (mice v3.11 and mitools v2.4 R packages) in which one hundred different datasets 132 were generated with imputed values and results were pooled; 3) any co-variable correlated with 133 fludrocortisone was introduced into the model to adjust its effects; and 4) intervention tested in 134 the SMART trial. The results of the regression models are presented with a point estimate odds 135 ratio and associated 95% confidence interval (CI) range. Significance was set at a two-tailed a 136 ≤0.05. All analyses were performed using R version 4.0.2 software (R Foundation for Statistical 137 Computing, Vienna, Austria). 138

139

140 **RESULTS**

141 Baseline Patient Characteristics

7

The median age of the 78 aSAH patients included in this study was 58 years (interquartile range, IQR, 49 to 64.5) and 50 patients (64%) were female. A total of 70 patients (90%) received an endovascular embolization of their ruptured aneurysm, 46 (59%) of which were in the anterior cerebral circulation. Forty-one patients (53%) were treated with fludrocortisone and 37 patients (47%) were not treated with fludrocortisone. Besides age, which was lower in the group treated with fludrocortisone, the two groups were similar at baseline (Table 1).

In the group that received fludrocortisone, the median dosage and the number of patients treated per ICU admission day are plotted in Figure 1. More patients treated with fludrocortisone were also co-treated with enteral salt [13 (32%) vs. 6 (16%); P=0.12] and hypertonic saline [23 (56%) vs. 6 (16%); P<0.01]. When used, the amount of enteral salt and hypertonic saline did not significantly differ between groups (Table 2).

154

155 Outcomes

Compared with patients who did not receive fludrocortisone, patients who received 156 fludrocortisone experienced a lower mRS scores at 90 days (adjusted common odds ratio, aOR, 157 of 0.33; 95% CI, 0.14 to 0.80; P=0.02), with values below 1.0 favoring receipt of fludrocortisone 158 (Figure 2; Table 3). Excluding the 6 patients who did not have a mRS score at 90 days resulted 159 160 in an aOR of 0.36 (95% CI, 0.14 to 0.92; P=0.03). Substituting them with imputed values resulted in an aOR of 0.36 (95% CI, 0.14 to 0.91; P=0.04). Because the use of enteral salt and 161 hypertonic saline correlated with the use of fludrocortisone (Table 3), we introduced these 162 variables in the regression model. Both did not independently correlate with the outcomes (use 163 of enteral salt aOR 0.5 [0.18-1.35]; P=0.17; and use of hypertonic saline aOR 1.30 [0.45-3.70]; 164 P=0.63), but the use of fludrocortisone maintained a similar association as in the primary 165 analysis (aOR 0.41 [0.15-1.04]; P=0.06). Because these patients were enrolled in the SMART 166

8

trial, comparing the primary use of balanced crystalloids to saline for intravenous fluid therapy, 167 we included the trial fluid assignment as an interaction variable in the model. Of the 41 patients 168 who received fludrocortisone, 21 were assigned saline and 20 were assigned a balanced 169 crystalloid; and of the 37 patients who did not receive fludrocortisone, 20 were assigned saline 170 and 17 were assigned a balanced crystalloid. In this model, the use of fludrocortisone continued 171 to maintain a similar association as in the primary analysis (aOR 0.15 [0.04-0.60]; P=0.01). The 172 use of saline was associated with better outcomes (aOR 0.24 [0.06-0.96]; P=0.05). Importantly, 173 in the model the interaction term of fluid assignment and fludrocortisone did not associate with 174 outcome (aOR 3.22 [0.50-21.6]; P=0.22). 175

Patients treated with or without fludrocortisone experienced similar incidences of organ dysfunction events (Table 4). Patients treated with fludrocortisone had higher but not statistically significant incidences of symptomatic vasospasm [17 (42%) vs 8 (22%); P=0.10], delayed cerebral ischemia events [17 (42%) vs 8 (22%); P=0.16], and pulmonary edema [6 (15%) vs 3 (8%); P=0.59]. No patient with fludrocortisone had cardiac dysfunction (0 (0%) vs 4 (11%); P=0.10). Length of hospital stay did not differ with the use of fludrocortisone (median 17 days [IQR 14-22] vs 16 [11-20]; Table 4).

183

184 **DISCUSSION**

The 2023 American Heart Association aSAH guidelines recommend that "the use of mineralocorticoids is reasonable to treat natriuresis and hyponatremia,"(12) citing its efficacy from randomized controlled trials (8). Natriuresis-driving hypovolemia can compromise organ perfusion, risking life-threatening ischemic strokes (in the setting of cerebral vasospasm), AKI, and cardiopulmonary dysfunction (11). Indeed, a meta-analysis showed that fludrocortisone reduces symptomatic vasospasm in aSAH patients (8). A 8346-patient population-based study showed that poor hemodynamic status (hyponatremia and hypovolemia) increases the risk of

9

adverse events from vasospasm (17) resulting in poor outcomes. A similar therapeutic effect of fludrocortisone has been observed in patients with TB meningitis who also exhibit natriuresisdriven hypovolemia and strokes (18). However, its impact on outcomes of aSAH patients is unclear and has not been reported since 1999 (19). In this retrospective study, we found that fludrocortisone therapy was independently associated with better outcomes following aSAH.

The results of our study must be interpreted within its limitations. First, this study has 197 inherent retrospective bias. Second, the effect size we observed is large and may be due to the 198 199 study's small sample size. The sample size was selected based on the identification and selection of a *consecutive* cohort of aSAH patients, which was facilitated by the SMART trial. 200 Third, conduct at a single center limits generalizability. Fourth, fludrocortisone was not 201 protocolized and was often started by some providers after the patient exhibited symptomatic 202 203 vasospasm and hypovolemia, weakening any causal link between the outcomes and fludrocortisone. Thus, the higher rate of symptomatic vasospasm and delayed cerebral ischemia 204 seen in the group treated with fludrocortisone should be interpreted with great caution. All prior 205 studies, including randomized controlled trials, have shown fludrocortisone is associated with 206 lower incidences of symptomatic vasospasm and delayed cerebral ischemia (8). However, it is 207 208 noteworthy that despite greater incidences of symptomatic vasospasm and delayed cerebral ischemia, the use of fludrocortisone in these patients was associated with better outcomes. Our 209 210 results must be confirmed with prospective randomized controlled trials.

211

212 CONCLUSIONS

In this retrospective cohort analysis, the use of fludrocortisone was associated with better outcomes in aSAH patients. This finding must be confirmed with a randomized controlled trial.

It is made available under a CC-BY-NC 4.0 International license .

217 **REFERENCES**

- 1. Chan V, Lindsay P, McQuiggan J, et al. Declining Admission and Mortality Rates for
- Subarachnoid Hemorrhage in Canada Between 2004 and 2015. Stroke 2019;50:181-184.
- 220 2. Lee VH, Ouyang B, John S, et al. Risk stratification for the in-hospital mortality in
- subarachnoid hemorrhage: the HAIR score. Neurocrit Care 2014;21:14-19.
- 3. Stienen MN, Germans M, Burkhardt JK, et al. Predictors of In-Hospital Death After
- Aneurysmal Subarachnoid Hemorrhage: Analysis of a Nationwide Database (Swiss SOS [Swiss
- Study on Aneurysmal Subarachnoid Hemorrhage]). Stroke 2018;49:333-340.
- 4. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid
- haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol
- 227 2009;8:635-642.
- 5. Chen S, Li Q, Wu H, et al. The harmful effects of subarachnoid hemorrhage on extracerebral
 organs. Biomed Res Int 2014;2014:858496.
- 6. Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and
 why? Crit Care 2015;19:309.
- 232 7. Solenski NJ, Haley EC, Jr., Kassell NF, et al. Medical complications of aneurysmal
- subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants
- of the Multicenter Cooperative Aneurysm Study. Crit Care Med 1995;23:1007-1017.
- 235 8. Mistry AM, Mistry EA, Ganesh Kumar N, et al. Corticosteroids in the Management of
- Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis.
- 237 Cerebrovasc Dis 2016;42:263-271.
- 238 9. Mistry AM, Magarik JA, Feldman MJ, et al. Saline versus Balanced Crystalloids for Adults
- with Aneurysmal Subarachnoid Hemorrhage: A Subgroup Analysis of the SMART Trial. Stroke
- 240 Vasc Interv Neurol 2022;2.

It is made available under a CC-BY-NC 4.0 International license .

- 10. Barlow B, Thompson Bastin ML, Shadler A, et al. Association of chloride-rich fluids and
- medication diluents on the incidence of hyperchloremia and clinical consequences in
- aneurysmal subarachnoid hemorrhage. J Neurocrit Care 2022;15:113-121.
- 11. Brown RJ, Epling BP, Staff I, et al. Polyuria and cerebral vasospasm after aneurysmal
- subarachnoid hemorrhage. BMC Neurol 2015;15:201.
- 12. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With
- 247 Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart
- Association/American Stroke Association. Stroke 2023;54:e314-e370.
- 13. Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically III
- Adults. N Engl J Med 2018;378:829-839.
- 14. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the
- assessment of handicap in stroke patients. Stroke 1988;19:604-607.
- 15. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after
- aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational
- studies: proposal of a multidisciplinary research group. Stroke 2010;41:2391-2395.
- 16. Rosengart AJ, Schultheiss KE, Tolentino J, et al. Prognostic factors for outcome in patients
- with aneurysmal subarachnoid hemorrhage. Stroke 2007;38:2315-2321.
- 17. Rumalla K, Lin M, Ding L, et al. Risk Factors for Cerebral Vasospasm in Aneurysmal
- Subarachnoid Hemorrhage: A Population-Based Study of 8346 Patients. World neurosurgery
 2021;145:e233-e241.
- 18. Misra UK, Kalita J, Kumar M. Safety and Efficacy of Fludrocortisone in the Treatment of
- 262 Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial.
- 263 JAMA Neurol 2018;75:1383-1391.

It is made available under a CC-BY-NC 4.0 International license .

- 19. Mori T, Katayama Y, Kawamata T, et al. Improved efficiency of hypervolemic therapy with
- inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid
- 266 hemorrhage. J Neurosurg 1999;91:947-952.

13

Table 1. Patient characteristics at baseline.

Patient characteristics ^a	No Fludrocortisone (n=37)	Fludrocortisone (n=41)	P value ^b
Age, median [IQR], yrs	61 [53-67]	55 [49-62]	0.04
Men, n (%)	12 (32%)	17 (42%)	0.56
Chronic comorbidities, n (%)			
Ischemic heart disease	2 (5%)	5 (12%)	0.52
Active tobacco smoking	12 (32%)	20 (49%)	0.22
Hypertension	31 (84%)	29 (71%)	0.27
Diabetes	5 (14%)	3 (7%)	0.60
Prior subarachnoid hemorrhage	2 (5%)	0 (0%)	0.43
Subarachnoid hemorrhage severity			
WFNS grade			0.72
Grade 1	7 (19%)	12 (29%)	
Grade 2	10 (27%)	12 (29%)	
Grade 3	3 (8%)	4 (10%)	
Grade 4	9 (24%)	6 (15%)	
Grade 5	8 (22%)	7 (17%)	
Hunt Hess score			0.47
Grade 1	0 (0%)	0 (0%)	
Grade 2	11 (30%)	14 (34%)	
Grade 3	9 (24%)	15 (37%)	
Grade 4	11 (30%)	8 (20%)	
Grade 5	6 (16%)	4 (10%)	
modified Fischer score			0.56
Score 1	1 (3%)	1 (2%)	
Score 2	3 (8%)	7 (17%)	
Score 3	8 (22%)	11 (27%)	
Score 4	25 (68%)	22 (54%)	
Aneurysm location, n (%)			>0.99
Anterior circulation	22 (59%)	24 (59%)	
Posterior circulation	15 (41%)	17 (41%)	
Aneurysm size, median [IQR], mm	4.6 [4.0-6.4]	5.4 [4.0-8.2]	0.22
Treatments received		• •	0.60
Clip obliteration, n (%)	5 (14%)	3 (7%)	
Endovascular embolization, n (%)	32 (86%)	38 (93%)	
Time from symptom onset to	1.46 [1.00-4.46]	1.54 [1.34-2.42]	0.82
surgical treatment, median [IQR],			
days CNS complications, n (%)			
Aneurysm re-rupture	1 (3%)	0 (0%)	0.96
Secondary open operation ^c	4 (11%)	0 (0%)	0.10
latrogenic stroke	3 (8%)	0 (0%)	0.20
Ventricular CSF diversion	24 (65%)	30 (73%)	0.58
CNS infection ^d	1 (3%)	4 (10%)	0.42

- ^aAbbreviations: CSF cerebrospinal fluid; CNS central nervous system; ICU intensive care
- 271 unit; IQR interquartile range; WFNS world federation of neurological surgeons
- ^bStatistical tests: Group differences were tested with a Chi-square test for categorical variables and Wilcoxon test for continuous variables.
- ^cSecondary open operation defined as craniotomy or craniectomy after completion for treatment of the aneurysm.
- ²⁷⁶ ^dCNS infection defined as infection of the central nervous system, meninges, or cerebrospinal
- fluid (microbiologically proven or clinical signs treated empirically with 4 or more consecutive
- 278 days of antibiotics).

Table 2. Sodium supplementation between ICU admission and day 14 in aSAH patients treated with and without fludrocortisone. 279

280

281

Sodium Replacement ^a	Fludrocortisone (n=41)	No Fludrocortisone (n=37)	P value
Hypertonic saline			
median [IQR], mL	4500 [1000-6000]	1625 [1062.50-5187.50]	0.79
n	13 (32%)	6 (16%)	0.12
Enteral salt			
median [IQR], g	14 [6-47.5]	11.5 [7.25-16.5]	0.40
n	23 (56%)	6 (16%)	<0.01

^aAbbreviations: aSAH – aneurysmal subarachnoid hemorrhage; ICU – intensive care unit; IQR – 282

283 interquartile range

Table 3. Ordinal regression models for 90-day modified Rankin Scale (mRS) scores.

Adjusted common odds ratios with 95% confidence intervals and corresponding P values are reported.

287

Co-variable	Effect size
Fludrocortisone (vs. no fludrocortisone)	0.33 [0.14-0.80], P=0.02
Age (continuous)	1.06 [1.02-1.10], P=0.01
Time to treatment (continuous)	1.00 [0.91-1.10], P=0.96
Hypertension (no hypertension as reference)	1.20 [0.44-3.31], P=0.72
Endovascular embolization (clip obliteration as reference)	1.01 [0.21-4.80], P=0.99
World Federation of Neurological Surgeon's grade (Grade 1 as	
reference)	
Grade 2	2.27 [0.67-7.88], P=0.19
Grade 3	4.70 [0.92-24.7], P=0.06
Grade 4	5.36 [1.50-20.2], P=0.01
Grade 5	18.7 [4.78-79.0], P<0.01

It is made available under a CC-BY-NC 4.0 International license .

289 Table 4. Outcomes

290

Outcome ^a	No Fludrocortisone (n=37)	Fludrocortisone (n=41)	Adjusted common odds ratio (95% CI)	P value ^c
Primary outcome				
mRS at 90 days, <i>n</i>	3 [2-4]	1 [1-2]	0.33 [0.14- 0.80] ^b	0.02
Secondary outcomes				
Clinical outcomes, n (%)				
Length of stay, days	16 [11-20]	17 [14-22]		0.39
Adverse organ-based events, n (%)				
Symptomatic vasospasm	8 (22%)	17 (42%)	-	0.10
Delayed cerebral ischemia	8 (22%)	16 (39%)	-	0.16
Pulmonary edema ^d	3 (8%)	6 (15%)	-	0.59
Cardiac dysfunction ^e	4 (11%)	0 (0%)	-	0.10

^aAbbreviations: CI – confidence interval; mRS – modified Rankin Scale

²⁹² ^bAdjusted common odds ratio from a proportional odds regression analysis

²⁹³ ^cGroup differences were tested with a Chi-square test for categorical variables and Wilcoxon

test for continuous variables; if odds ratios are presented, associated P values are presented

^dPulmonary edema evidenced by a chest radiograph and/or initiation of a diuretic treatment with the goal of treating pulmonary edema.

²⁹⁷ ^eCardiac dysfunction defined as myocardial infarction, new onset of heart failure, or initiation of

ionotropic therapy.

It is made available under a CC-BY-NC 4.0 International license .

299 **FIGURE LEGENDS**

Figure 1. Fludrocortisone use in aneurysmal subarachnoid hemorrhage patients. The median dose of fludrocortisone (blue line) with interquartile range (light blue shade) and the number of patients treated with fludrocortisone (red line) are plotted against the postsubarachnoid hemorrhage day.

304

305

Figure 2. Functional outcomes of patients with aneurysmal subarachnoid hemorrhage treated with and without fludrocortisone. Distribution of scores on the modified Rankin scale (mRS) at 90 days according to the treatment with fludrocortisone. The mRS ranges from a score of 0, indicating no symptoms, to a score of 6, indicating death. The numbers within the bars are percentages of patients who attained the score.





